Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

DSpace Repository

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Author: Maio, Michele; Grob, Jean-Jacques; Aamdal, Steinar; Bondarenko, Igor; Robert, Caroline; Thomas, Luc; Garbe, Claus; Chiarion-Sileni, Vanna; Testori, Alessandro; Chen, Tai-Tsang; Tschaika, Marina; Wolchok, Jedd D.
Tübinger Autor(en):
Garbe, Claus
Published in: Journal of Clinical Oncology (2015), Bd. 33, H. 10, S. 1191-1196
Verlagsangabe: Amer Soc Clinical Oncology
Language: English
Full text: http://dx.doi.org/10.1200/JCO.2014.56.6018
ISSN: 0732-183X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)